Search Results

Late in 2021, Aerogen® and CanSinoBIO announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIO’s Recombinant Novel Coronavirus Vaccine Convidecia Air™ utilizing Aerogen’s proprietary aerosol drug delivery technology.

Following months of collaborative development work, Aerogen® and CanSinoBIO have announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIO’s Recombinant Novel Coronavirus Vaccine Convidecia™ utilizing Aerogen’s proprietary vibrating mesh aerosol drug delivery technology.

Synairgen’s SNG001 among the many potential treatments and vaccines to be delivered via Aerogen’s aerosol drug delivery system Adds to the thousands of COVID-19 patients already safely and effectively treated with Aerogen’s Solo aerosol drug delivery system in the intensive care unit 1 Aerogen technology is featured in guidelines and papers on the treatment of COVID-19 patients across the globe 2 , 3 , 4

Aerogen Pharma, and Nuance Pharma (“Nuance”), today announce an exclusive agreement to join forces in Greater China to develop a superior, non-invasive approach to treatment of RDS, a life-threatening condition of preterm infants associated with long-term lung health issues in survivors.

Aerogen today announced that Temasek, a global investment company headquartered in Singapore, has acquired a minority stake in Aerogen through the purchase of a secondary share interest. Financial terms of the transaction were not disclosed.